R&D Trends

U.K. government awards $2.7M grant to PsiOxus cancer vaccine

Wednesday, November 7, 2012 10:57 AM

PsiOxus Therapeutics, a development stage biotechnology company based in the U.K was awarded a $2.7 million grant from the U.K. government-backed Biomedical Catalyst to initiate a phase I/II clinical trial to assess the use of ColoAd1 in the treatment of platinum-resistant, recurrent ovarian cancer.

More... »

Curie-Cancer, Harmonic to explore anti-cancer activity of several compounds

Monday, November 5, 2012 03:21 PM

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and Harmonic Pharma, a French company focused on extending the therapeutic application of compounds already on the market, have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic’s portfolio.

More... »

More than $1.6B to be invested in U.K. science and research

Friday, November 2, 2012 02:48 PM

Seven new university and business research projects won bids from the U.K. Research Partnership Investment Fund (UK RPIF), doubling the number of winning bids to 14. When complete, the scheme will deliver more than $1.6 billion of new funding for research from government, industry and charities.

More... »

Portola, BMS, Pfizer ink collaboration on study on reversing anticoagulation

Friday, November 2, 2012 01:57 PM

Portola Pharmaceuticals, a therapeutics company focused on thrombosis, inflammatory disease and cancer, global biopharmaceutical company Bristol-Myers Squibb (BMS) and Pfizer have signed a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Elquis (apixaban).

More... »

Vertex, GSK partner on phase II all-oral study of VX-135, GSK2336805 for Hep C

Friday, November 2, 2012 11:23 AM

Vertex Pharmaceuticals, a global biotechnology company based in Cambridge, Mass., has entered into a non-exclusive agreement with GlaxoSmithKline (GSK) to conduct a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing Vertex's nucleotide analogue HCV polymerase inhibitor VX-135 and GSK's NS5A inhibitor GSK2336805.

More... »

Ensemble, Boehringer Ingelheim collaborate on macrocycle drug candidates

Friday, November 2, 2012 10:56 AM

Ensemble Therapeutics of Cambridge, Mass., has initiated a research collaboration with Germany-based Boehringer Ingelheim to discover drug candidates of a novel class of small molecule drugs, called macrocycles, against several high-value pharmaceutical targets specified by Boehringer Ingelheim.

More... »

$11.3M awarded to researchers through MRC-AZ compound collaboration

Thursday, November 1, 2012 09:56 AM

The Medical Research Council (MRC) has awarded $11.3 million of funding for 15 research projects awarded through its collaboration with global biopharmaceutical company AstraZeneca, which gave academic researchers unprecedented access to 22 chemical compounds.

More... »

Charles River to acquire Vital River, expands research models business

Thursday, November 1, 2012 09:28 AM

Charles River Laboratories International, a global provider of research products and services, has entered into an agreement to acquire 75% ownership of Vital River, a Chinese commercial provider of research models and related services.

More... »

Apredica, Pfizer ink collaborative research agreement

Wednesday, October 31, 2012 09:43 AM

Apredica, a subsidiary of Cyprotex, a preclinical ADME-Tox services company, has signed a collaborative research agreement with Pfizer, a global research-based pharmaceutical company.

More... »

Evotec, CHDI Foundation extend collaboration in Huntington's

Tuesday, October 30, 2012 12:23 PM

CHDI Foundation, a privately-funded not-for-profit research organization dedicated to developing therapies for Huntington's disease, has extended its collaboration with Evotec, a drug discovery alliance and development partnership company based in Germany, until the end of 2015. The contract extension could be worth up to $41 million in research payments for Evotec.

More... »